Why HERZUMA? Download  brochure

Image of model’s portrayal of patient

get to know


What is HERZUMA?


HERZUMA is not chemotherapy, though it is sometimes used with chemotherapy. HERZUMA is a type of treatment called an antibody therapy. This means HERZUMA is able to treat HER2+ breast cancer cells, which can multiply rapidly.

Actor portrayal.

HERZUMA is a type of biologic called a biosimilar

Biosimilars are FDA-approved biological products that are highly similar and have no clinically meaningful differences from existing FDA-approved biologic drugs. Biologics are complex drugs produced from living cells. HERZUMA is a biosimilar of the drug Herceptin® (trastuzumab) for HER2+ breast cancer. Biosimilars like HERZUMA offer doctors and patients more choices in medications.

3-D images of two molecules showing biosimilarity between biologic and biosimilar

How HERZUMA works


  • By binding to the HER2 receptor on cancer cells
  • By telling the immune system it's okay to destroy cancer cells
  • By destroying cancer cells on its own

HERZUMA may also harm some healthy cells in the body. Talk to your doctor about any concerns you may have.

HER2+ = Human Epidermal growth factor Receptor 2-positive.

What are the goals of treatment?

See HERZUMA treatment goals


Patients are selected for therapy with HERZUMA based on an FDA-approved test.

Adjuvant Breast Cancer

HERZUMA is a prescription medicine used for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature. HERZUMA can be used in several different ways:

  • As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as “AC TH”
  • With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as “TCH”
  • Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin)-based therapy (a type of chemotherapy)

Patients are selected for therapy with HERZUMA based on an FDA-approved test.

Metastatic Breast Cancer

HERZUMA has 2 approved uses in metastatic breast cancer:

  • HERZUMA in combination with the chemotherapy drug paclitaxel is approved for the first-line treatment of Human Epidermal growth factor Receptor 2-positive (HER2+) metastatic breast cancer
  • HERZUMA alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease

Patients are selected for therapy with HERZUMA based on an FDA-approved test.


HERZUMA can cause serious side effects, including:

  • HEART PROBLEMS: Trastuzumab products can cause heart problems—such as congestive heart failure or reduced heart function—with or without symptoms. The risk for and seriousness of these heart problems were highest in people who received both a trastuzumab product and a certain type of chemotherapy (anthracycline). In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your healthcare provider will check for signs of heart problems before, during, and after treatment with HERZUMA
  • INFUSION REACTIONS: Infusion reactions, sometimes serious or fatal, have occurred. Symptoms may include: fever, chills, feeling sick to your stomach (nausea), throwing up (vomiting), pain (in some cases at tumor site), headache, dizziness, and shortness of breath. These symptoms usually happen within 24 hours after receiving HERZUMA
  • SEVERE LUNG PROBLEMS: Trastuzumab product use can result in serious and fatal lung problems. Symptoms may include: severe shortness of breath, fluid in or around the lungs, weakening of the valve between the heart and lungs, not enough oxygen in the body, swelling of the lungs, and scarring of the lungs. Your healthcare provider may check for signs of severe lung problems
  • HARM TO UNBORN BABIES OR BIRTH DEFECTS: Trastuzumab products may result in birth defects or the death of an unborn baby. Contraception should be used while receiving HERZUMA and for 7 months after your last dose of HERZUMA. If you are or become pregnant while receiving HERZUMA or within 7 months after your last dose of HERZUMA, you should immediately contact your doctor. Patients should contact their healthcare professional with a known or suspected pregnancy
  • LOW WHITE BLOOD CELL COUNTS: Low white blood cell counts (which may be life-threatening) were seen more often in patients receiving trastuzumab plus chemotherapy than in patients receiving chemotherapy alone. Your healthcare provider may check for signs of low white blood cell counts

Your healthcare provider will stop treatment with HERZUMA if you have severe, serious, or life-threatening side effects.

The most common side effects for patients receiving HERZUMA for breast cancer include: headache, diarrhea, feeling sick to your stomach (nausea), chills, fever, infection, weakened heart muscle, unable to sleep, cough, and rash.

These are not all of the possible side effects with HERZUMA. Talk to your doctor about any side effects you may experience.

Please see full Prescribing Information, including BOXED WARNINGS.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.

You are about to leave HERZUMA and enter a website operated by a third party.

Would you like to continue?

The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?